IL2 and neoplasm: In particular, several therapeutic agents have been developed to stimulate NK cells using cytokines or mutant cytokines54, such as NK cell engagers armed with IL-2 variants52, and it is crucial to consider the cytokine sensitivity of tumor-associated NK cells.